Lonza Group AG (LONN)

445.00
+4.80(+1.09%)
  • Volume:
    251,738
  • Bid/Ask:
    445.00/445.10
  • Day's Range:
    441.80 - 453.50

LONN Overview

Prev. Close
440.2
Day's Range
441.8-453.5
Revenue
4.14B
Open
443.7
52 wk Range
437.1-779.2
EPS
41.99
Volume
251,738
Market Cap
33.43B
Dividend (Yield)
1.50
(0.34%)
Average Vol. (3m)
160,553
P/E Ratio
12.57
Beta
0.655
1-Year Change
-40.72%
Shares Outstanding
74,189,129
Next Earnings Date
Oct 25, 2022
What is your sentiment on Lonza Group?
or
Market is currently closed. Voting is open during market hours.

Lonza Group AG News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Lonza Group AG Analysis

Lonza Group AG Company Profile

Lonza Group AG Company Profile

Employees
17154
  • Type:Equity
  • Market:Switzerland
  • ISIN:CH0013841017
  • S/N:1384101

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Read More

Analyst Price Target

Average768.02 (+72.59% Upside)
High926.26
Low325
Price445
No. of Analysts17
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsSellSellBuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralStrong SellStrong Sell
  • My best friend works for Lonza in Spain... It's an amazing company and works for top bio companies like Moderna, Bointech or Bayer among others....
    0
    • Lonza growing fast. Visp growing as well. now starting with the vaccine production. Solid company.
      0
      • 600 target price
        0
        • based on what ?
          0
      • lonza new CEO
        0
        • do we know the reason Mr. Singarella ?
          0
          • Forecast https://walletinvestor.com/stock-forecast/lzagf-stock-prediction
            0
        • Seems this will keep going up
          0